Kedrion Faces Supply Chain Hurdles Amid Global Tensions

Kedrion, an Italian biopharmaceutical leader, is facing potential challenges in the delivery of plasma-derived therapies to Iran, especially if the ongoing geopolitical tensions escalate. The company's CEO, Ugo Di Francesco, cautioned about surging logistics costs due to escalating fuel prices, which could hinder timely deliveries.

The company has so far maintained its capacity to provide life-saving treatments for rare diseases, despite the external pressures. Kedrion operates 76 plasma collection centers, with a significant presence in the U.S. and a merger with Britain's Bio Products Laboratory cementing its global standing.

Financially, Kedrion has reported a steady rise with a revenue of €1.65 billion in 2025, a 4.5% increase from the previous year. The U.S. market remains pivotal, constituting 61% of total revenue, with expectations to grow further in the coming years.

(With inputs from agencies.)